Vitrolife Group
Bronwyn Brophy is a seasoned executive with extensive experience in the medical technology sector. Currently serving as the Chief Executive Officer at Vitrolife Group since August 2023, Bronwyn has previously held significant leadership roles, including Vice Chair and Member of the Operations Management Committee at MedTech Europe, and Global President Immunodiagnostics at Thermo Fisher Scientific. With a robust background that spans various aspects of business management, including P&L responsibility, R&D, operations, and commercial strategies, Bronwyn has driven growth initiatives in multiple companies such as Medtronic and Cordis. Educational qualifications include an MBA from Dublin City University and a B.A. in International Marketing & Languages, reflecting a strong foundation in business management and strategic planning.
This person is not in any offices
Vitrolife Group
The Vitrolife Group is a world-leading global provider of medical devices and genetic testing services. Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarly for IVF clinics. Together we are now the Vitrolife Group, a global leader in reproductive health focused on supporting our customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality. Currently, we are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 125 countries, through our own presence in more than 25 countries and a vast network of distributors for the rest of the world. We are on a mission to be the leading global partner in reproductive health, striving for better treatment outcomes for patients.